Published in PLoS One on August 29, 2016
Chinese health care system and clinical epidemiology. Clin Epidemiol (2017) 0.75
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Economic costs of diabetes in the U.S. in 2012. Diabetes Care (2013) 11.74
Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract (2010) 5.16
Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care (2000) 4.62
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev (2003) 1.80
Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care (2009) 1.30
How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China? Value Health (2009) 1.12
Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS One (2012) 1.10
A systematic review of the direct economic burden of type 2 diabetes in china. Diabetes Ther (2015) 0.97
Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther (2008) 0.87
Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. Value Health (2012) 0.86
Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health (2008) 0.85
EHR adoption across China's tertiary hospitals: a cross-sectional observational study. Int J Med Inform (2013) 0.85
Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther (2010) 0.83
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care (2012) 0.83
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics (2015) 0.83
Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. J Med Econ (2015) 0.79
[Discussion on developing a data management plan and its key factors in clinical study based on electronic data capture system]. Zhong Xi Yi Jie He Xue Bao (2012) 0.78
Progress and policy implication of the Insurance Programs for Catastrophic Diseases in China. Int J Health Plann Manage (2017) 0.75